Literature DB >> 16246268

Purification of full-length human pregnane and xenobiotic receptor: polyclonal antibody preparation for immunological characterization.

Mallampati Saradhi1, Biji Krishna, Gauranga Mukhopadhyay, Rakesh K Tyagi.   

Abstract

Pregnane and Xenobiotic Receptor (PXR; or Steroid and Xenobiotic Receptor, SXR), a new member of the nuclear receptor superfamily, is thought to modulate a network of genes that are involved in xenobiotic metabolism and elimination. To further explore the role of PXR in body's homeostatic mechanisms, we for the first time, report successful prokaryotic expression and purification of full-length PXR and preparation of polyclonal antibody against the whole protein. The full-length cDNA encoding a 434 amino acids protein was sub-cloned into prokaryotic expression vector, pET-30b and transformed into E. coli BL21(DE3) cells for efficient over expression. The inclusion body fraction, containing the expressed recombinant protein, was purified first by solubilizing in sarcosine extraction buffer and then by affinity column chromatography using Ni-NTA His-Bind matrix. The efficacy of anti-PXR antibody was confirmed by immunocytology, Western blot analysis, EMSA and immunohistochemistry. The antibody obtained was capable of detecting human and mouse PXR with high specificity and sensitivity. Immunofluorescence staining of COS-1 cells transfected with human or mouse PXR showed a clear nuclear localization. Results from immunohistochemistry showed that level of PXR in liver sections is immunologically detectable in the nuclei. Similar to exogenously transfected PXR, Western blot analysis of cell extract from HepG2 and COLO320DM cells revealed a major protein band for endogenous PXR having the expected molecular weight of 50 kDa. Relevance of other immunodetectable bands with reference to PXR isoforms and current testimony are evaluated. Advantages of antibody raised against full-length PXR protein for functional characterization of receptor is discussed and its application for clinical purposes is envisaged.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16246268     DOI: 10.1038/sj.cr.7290348

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  6 in total

1.  Protein phosphatase 2Cbetal regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells.

Authors:  Satyanarayana R Pondugula; Alexander A Tong; Jing Wu; Jimmy Cui; Taosheng Chen
Journal:  Drug Metab Dispos       Date:  2010-06-10       Impact factor: 3.922

2.  In vitro and in vivo evaluation of the toxicities induced by metallic nickel nano and fine particles.

Authors:  Ruth Magaye; Yuanliang Gu; Yafei Wang; Hong Su; Qi Zhou; Guochuan Mao; Hongbo Shi; Xia Yue; Baobo Zou; Jin Xu; Jinshun Zhao
Journal:  J Mol Histol       Date:  2016-03-24       Impact factor: 2.611

3.  A phosphomimetic mutation at threonine-57 abolishes transactivation activity and alters nuclear localization pattern of human pregnane x receptor.

Authors:  Satyanarayana R Pondugula; Cynthia Brimer-Cline; Jing Wu; Erin G Schuetz; Rakesh K Tyagi; Taosheng Chen
Journal:  Drug Metab Dispos       Date:  2009-01-26       Impact factor: 3.922

4.  Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells.

Authors:  Wenwei Lin; Jing Wu; Hanqing Dong; David Bouck; Fu-Yue Zeng; Taosheng Chen
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

Review 5.  Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression.

Authors:  Satyanarayana R Pondugula; Hanqing Dong; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-08       Impact factor: 4.481

6.  Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate.

Authors:  Lichen Gao; Yijing He; Jie Tang; Jiye Yin; Zhengyu Huang; Fangqun Liu; Dongsheng Ouyang; Xiaoping Chen; Wei Zhang; Zhaoqian Liu; Honghao Zhou
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.